(C) Vietbao.vn

SEOUL — A breakthrough in precision oncology is paving the way for a future where a simple blood draw could provide a more comprehensive genetic map of ovarian cancer than traditional, invasive tissue biopsies.

According to a study recently published in the International Journal of Molecular Sciences (IJMS), researchers from the Korea University College of Medicine have successfully utilized Macrogen’s "Axen Cancer Panel 2" to detect genetic signals of cancer in the blood of patients with High-Grade Serous Ovarian Cancer (HGSOC).

Beyond the Needle: The Power of cfDNA
The study, led by Professor Song Jae-yun, analyzed 12 HGSOC patients by comparing plasma cell-free DNA (cfDNA) with matched tumor tissue. The results were striking: the blood-based testing showed a 95.3% concordance rate with tissue samples at the genetic level (including negative agreement for non-mutated genes).

More importantly, the liquid biopsy proved to be more sensitive in identifying the "breadth" of the cancer’s genetic profile. While traditional tissue biopsies detected an average of 5.50 genetic variants per patient, the Axen Cancer Panel 2 identified an average of 9.67 variants.

This does not necessarily mean more cancer was "diagnosed," but rather that a more extensive list of genetic alterations was uncovered. This suggests that blood tests could identify more potential therapeutic targets—specific mutations that respond to certain drugs—which might be missed by a single-site tissue biopsy.

The 'Molecular Mirror' Effect
One of the primary limitations of a traditional biopsy is "spatial heterogeneity." Because a needle only samples a tiny portion of a tumor, it often misses the genetic diversity found in other parts of the mass or in metastatic lesions located elsewhere in the body.

The research team described the liquid biopsy as a "molecular mirror." Since cancer cells from various lesions across the body shed DNA into the bloodstream, a blood test can capture an integrated signal of the entire tumor burden. This provides a holistic view of the cancer’s genetic evolution as it spreads, a feat nearly impossible with localized tissue sampling.

Tracking Cancer Progression
The study also established a significant correlation between the volume of genetic material in the blood and the stage of the cancer. Higher levels of cfDNA were associated with more advanced stages of the disease.

Because blood tests are significantly less taxing on the patient than repeated surgeries or needle biopsies, this technology holds immense potential for long-term monitoring. Doctors could theoretically track the "tumor burden" in real-time, observing how a patient responds to treatment or detecting a relapse long before it becomes visible on an imaging scan.

A Complementary Future
Despite the promising results, experts remain cautious about completely replacing the gold standard of tissue biopsy just yet. The study reported a sensitivity of 57.6% in reproducing specific tissue-confirmed mutations in the blood.

"This pilot study demonstrates that liquid biopsies can serve as a powerful complementary tool to traditional biopsies," a representative from the research team stated. "While it offers a broader genetic perspective, further large-scale studies are needed to validate its effectiveness in tracking the entire treatment process over time."

As genomic technology continues to advance, the integration of tools like the Axen Cancer Panel 2 into clinical practice could mark a shift toward "minimalist" diagnostics with "maximalist" data, offering ovarian cancer patients more personalized and less painful paths to recovery.